# US 2001/0027182 A1 · Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfilind in sca1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027182 A1
- Document ID: US20010027182A1
- Status: Published application
- Kind: A1
- Application number: 09/321,916
- Filed: 1999-05-28
- Published: 2001-10-04
- Earliest claimed: 1998-05-29
- Inventors: HUDA Y. ZOGHBI; HARRY T. ORR; DONALD B. DEFRANCO; MICHAEL A. MANCINI; DAVID STENOIEN; CHRISTOPHER J. CUMMINGS
- Web page: https://patentgrep.com/patent/US20010027182A1

## CPC

- A61K 38/1709: {from mammals}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a novel method for treating neurodegenerative disease in mammals. This method involves the introduction of a therapeutic effective amount of a chaperone, a chaperone-like-compound or a compound which increases proteasome activity into the neurological system of the mammal. There is also a novel method for screening for compounds having chaperone-like activity or having activity to increase proteasome activity. The screening works in either cultured cells or animal models.

## Claims

### Claim 1

A method of treating neurodegenerative disease in a mammal comprising the steps of introducing a therapeutic effective amount of a chaperone or chaperone-like-compound into the neurological system of the mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein the introducing step includes introducing the chaperone or chaperone-like-compound into the mammal by gene therapy.

### Claim 3 (depends on 1)

The method of claim 1, wherein the introducing step includes directly injecting the chaperone or chaperone-like-compound into the mammal.

### Claim 4

A method for screening for a test compound for chaperone-like activity for the treatment of neurodegenerative diseases comprising the steps of:
introducing the test compound into transfected cells in tissue culture, wherein such transfected cells produce protein aggregate; and
measuring the quantity of protein aggregate, wherein a test compound which decreases the quantity of protein aggregate as compared to control cells has chaperone activity.

### Claim 5

A method for screening for a test compound for chaperone-like activity for the treatment of neurodegenerative diseases comprising the steps of:
introducing the test compound into an animal which models neurodegenerative disease;
allowing said animal to develop; and
subsequently measuring the quantity of aggregates in said animal wherein decreased aggregate formation over control animals indicates chaperone-like activity.

### Claim 6

A method of treating neurodegenerative disease in a mammal comprising the step of introducing a therapeutically effective amount of a compound into said mammal wherein said compound increases the effective concentration of a chaperone in the neurological system.

### Claim 7

A method of treating neurodegenerative disease in a mammal comprising the step of introducing a therapeutically effective amount of a compound into said mammal wherein said compound increases the effective concentration or enhances the activity of a proteasome in the neurological system.

### Claim 8

A method for screening for a test compound which increases proteasome activity for the treatment of neurodegenerative diseases comprising the steps of:
introducing the test compound into transfected cells in tissue culture, wherein such transfected cells produce protein aggregate; and
measuring the quantity of protein aggregate, wherein a test compound which decreases the quantity of protein aggregate is selected.

### Claim 9

A method for screening for a test compound which increases proteasome activity for the treatment of neurodegenerative diseases comprising the steps of:
introducing the test compound into an animal which models neurodegenerative disease;
allowing said animal to develop; and
subsequently measuring the quantity of aggregates in said animal wherein a compound which shows decreased aggregate formation over control animals is selected.

### Claim 10

Transgenic mice capable of overexpression of HDJ-2.
